Evolving Insights Within the Biosimilars Landscape: A Fireside Chat
Ryan Haumschild, PharmD, MS, MBA, CPEL, and Casey Butrus, PharmD, discuss the challenges related to stakeholder adoption of biosimilars, such as perspectives from pharmacy benefit managers, regional payers, health systems, and private label agreements, and assess strategies to enhance market uptake.
Episodes
December 21st 2024EP. 1: Clinical Value of Biosimilars and the Role of Interchangeability
A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.
February 10th 2025EP. 2: The Economic Impact of Biosimilars
Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.
February 10th 2025EP. 3: Best Practices for Employers to Maximize Uptake of Biosimilars
Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.
February 17th 2025EP. 4: The Role of Private Label Agreements in Enhancing Access to Biosimilars
Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.
February 17th 2025EP. 5: Key Structural and Operational Considerations for Biosimilar Adoption
Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.
